17 Stocks Jim Cramer Talked About

6. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holdings: 114

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% year-to-date. Freedom Capital discussed the firm in February as it raised the share price target to $1,200 from $1,050 and upgraded the stock to Buy. The coverage came after Eli Lilly and Company (NYSE:LLY) reported its fiscal fourth quarter and full year 2025 earnings, with Freedom Capital left impressed by the earnings beat due to strong momentum in weight loss drug sales. Deutsche Bank also discussed Eli Lilly and Company (NYSE:LLY) in February. It reiterated a Buy rating and a $1,200 share price target for the firm on the back of fiscal year 2026 projections. Eli Lilly and Company (NYSE:LLY)’s earnings report saw the firm guide $80 billion to $83 billion in revenue and $33.50 – $35 in non-GAAP earnings per share to beat analyst estimates for both of the metrics. Cramer commented on Eli Lilly and Company (NYSE:LLY)’s lead on Novo Nordisk in this appearance:

“Picked up a couple of points of share against Novo. And Novo, a lot of people feel, Novo’s been left behind. Remember, Novo had a big manufacturing problem, shortage problem where a lot of people switched to Mounjaro.

“I thought that he [CEO] acquitted himself well. But remember, the pill is really taking the country by storm. And there’s a lot of people who are going to take it, because pill form’s is a lot easier than injection.”